- Citi initiated coverage on Mersana Therapeutics Inc (NASDAQ:MRSN) with a Buy rating and a price target of $12.
- The analyst says the topline registrational data (expected in mid-2023) from the UPLIFT Ph2 study evaluating upifitamab rilsodotin (UpRi; NaPi2b ADC) in platinum-resistant ovarian cancer (PROC) will be a catalyst of significant debate.
- Citi analyst says that while readout will be binary, investors are underappreciating UPLIFT’s probability of success in NaPi2b-high patients, given the promising efficacy observed in Phase 1.
- If the UPLIFT study results are positive, it will lead to a clear pathway to an accelerated approval filing by YE23.
- The analyst writes that UpRi’s durability in Phase 1 was in-line or better than single-agent chemo SOC and the recently approved ADC Elahere.
- On toxicity, reduced dosing and patient selection strategies should mitigate the risk of Gr4/5 pneumonitis seen earlier in Phase 1.
- In December, Mersana announced its third significant collaboration agreement in 2022, reflecting its increasing role as an ADC partner.
- The company announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA (OTC:MKKGY) to discover novel Immunosynthen ADCs directed against up to two targets.
- Mersana received an upfront payment of $30 million and is eligible to receive reimbursement of certain costs, up to $800 million in potential milestone payments.
- Price Action: MRSN shares are up 10.48% at $6.43 on the last check Friday.
- Photo Via Company
Triple Flag Signs Definitive Agreements For Acquisition Of Gross Revenue Return And Stream On Prieska
Triple Flag Precious Metals Corp. (with its subsidiaries, “Triple Flag” or the “Company”) (TSX:TFPM, NYSE:TFPM) announced today that its wholly owned subsidiaries have entered into definitive
